Literature DB >> 25327162

In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model.

Zhongchan Sun1, Xinxing Song, Xiujuan Li, Tao Su, Shun Qi, Ruirui Qiao, Fu Wang, Yi Huan, Weidong Yang, Jing Wang, Yongzhan Nie, Kaichun Wu, Mingyuan Gao, Feng Cao.   

Abstract

miRNA-16 (miR16) plays an important role in modulating the drug resistance of SGC7901 cell lines to adriamycin (ADR). A variety of viral carriers have been designed for miRNA delivery. However, the safety concerns are currently perceived as hampering the clinical application of viral vector-based therapy. Herein a type of magnetic nanoparticles (MNPs) was designed and synthesized using poly(ethylene glycol) (PEG)-coated Fe₃O₄ nanoparticles as a miRNA delivery system for the purpose of reducing drug resistance of gastric cancer cells by enforcing miR16 expression in SGC7901/ADR cells. The MNPs with good biocompatibility were synthesized by thermal decomposition, and then conjugated with miRNA via electrostatic interaction producing miR16/MNPs. After co-culture with miR16/MNPs, ADR-induced apoptosis of SGC7901/ADR was examined by MTT and TUNEL. miR16/MNPs treatment significantly increased cell apoptosis in vitro. SGC7901/ADR(fluc) tumor-bearing nude mice under ADR therapy were treated with miR16/MNPs by tail vein injection for in vivo study. After intraperitoneal injection of ADR, tumor volume measurement and fluorescence imaging were performed to for the death of SGC7901/ADR cells in vivo. Results showed that miR16/MNPs were able to significantly suppress SGC7901/ADR tumor growth, probably through increasing SGC7901/ADR cells' sensitivity to ADR. Our results suggest the efficient delivery of miR16 by MNPs as a novel therapeutic strategy for drug resistant tumor treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25327162     DOI: 10.1039/c4nr03003f

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  11 in total

Review 1.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 2.  Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.

Authors:  Lei Zhu; Zhiyang Zhou; Hui Mao; Lily Yang
Journal:  Nanomedicine (Lond)       Date:  2016-11-23       Impact factor: 5.307

Review 3.  miRNA nanotherapeutics for cancer.

Authors:  Aditya Ganju; Sheema Khan; Bilal B Hafeez; Stephen W Behrman; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Discov Today       Date:  2016-11-01       Impact factor: 7.851

Review 4.  MicroRNA Therapeutics: the Next Magic Bullet?

Authors:  Bridget Simonson; Saumya Das
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

Review 5.  MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers.

Authors:  Jana Merhautova; Regina Demlova; Ondrej Slaby
Journal:  Front Pharmacol       Date:  2016-09-27       Impact factor: 5.810

Review 6.  MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy.

Authors:  Maddalena Mognato; Lucia Celotti
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

7.  Translational control of enzyme scavenger expression with toxin-induced micro RNA switches.

Authors:  Nina M Pollak; Justin J Cooper-White; Joanne Macdonald
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

8.  Zinc oxide nanoparticles reduce the chemoresistance of gastric cancer by inhibiting autophagy.

Authors:  You-Han Miao; Li-Ping Mao; Xiao-Juan Cai; Xiao-Ying Mo; Qi-Qi Zhu; Fei-Tong Yang; Mei-Hua Wang
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

9.  MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer.

Authors:  Yanjun Qu; Haiyang Zhang; Jingjing Duan; Rui Liu; Ting Deng; Ming Bai; Dingzhi Huang; Hongli Li; Tao Ning; Le Zhang; Xia Wang; Shaohua Ge; Likun Zhou; Benfu Zhong; Guoguang Ying; Yi Ba
Journal:  Oncotarget       Date:  2016-05-31

Review 10.  Non-coding RNA in drug resistance of gastric cancer.

Authors:  Ya-Jun Luo; Qing-Mei Huang; Yan Ren; Zi-Lin Liu; Cheng-Fei Xu; Hao Wang; Jiang-Wei Xiao
Journal:  World J Gastrointest Oncol       Date:  2019-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.